nivolumab,ipilimumab,cabozantinib
bms
['nivolumab', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'cabo ', 'nivo', 'cosmic-313']
cosmic-313 trial: pfs benefit of triplet (cabo + nivo + ipi) vs control (placebo + nivo + ipi) maintained with additional follow-up of ~5 months. overall population:hr 0.74 (95% ci 0.61-0.90). intermediate-risk patients (exploratory):hr 0.68 (95% ci 0.54-0.86). #gu23 
Jefe de Servicio de Oncología Médica. Hospital Universitario Lucus Augusti, HULA. Grupo de Investigación Oncológica Traslacional, GIOT HULA. Cuenta personal